DOCSLIB.ORG

612.399Vit3rdedref.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
612.399Vit3rdedref.Pdf Index Acidemia, radiographic findings, 880 Akt Anticonvulsants, vitamin D metabolism Arne, vitamin D therapy, 1898 cell differentiation induction via vitamin D, effects, 1257-1258 Actin, vitamin D binding protein complex, 1628-1629 Antimicrobial peptides, vitamin D effects on 65-66 leukemia signaling and vitamin D effects, expression, 1781-1783, 1813-1814 Actinic keratosis, vitamin D therapy, 1739 AP-l, see Activator protein-l 1898 photoprotection mechanisms of vitamin D Apoptosis Activator protein-l (AP-l), cell compounds, 1948 breast cancer cells, 1658-1659 differentiation induction via Alcohol calbindin D function, 369-370 vitamin D, 1631 alcoholism cancer and vitamin D, 1602-1603 AD, see Alzheimer's disease cirrhosis and bone loss leukemia, 1737 ADAM17, vitamin D renoprotective actions, clinical features, 1312 osteoclast, 339 1342-1345 epidemiology, 1311-1312 prostate cancer, 1685 Adipocyte pathogenesis, 1312-1313 Arsenic trioxide, leukemia treatment with vitamin D effects, 770-773 treatment, 1313 vitamin D combination therapy, vitamin D sequestration, 1019 hypophosphatemia, 1175 1740 Adolescent vitamin D metabolism effects, 1259-1260 Arteriosclerosis asthma and vitamin D status, 671 Aldosterone, see Renin-angiotensin system calcium-sensing receptor defects, calcium Alfacalcidol 1417-1418 absorption enhancers, 653-654 chemical synthesis, 1490-1491 vitamin D retention markers, 667 history of development, 1489-1490 calcium, phosphate, and vitamin D diabetes and vitamin D status, 671 multiple sclerosis treatment, 1865 excess effects, 1141 influenza and vitamin D status, osteoporosis management, 1491-1495 fibroblast growth factor-23/klothol 671 Alien, vitamin D receptor repression, vitamin D axis, 1413-1414 pubertal bone acquisition, 657-659 202-203 intervention studies vitamin D Alkaline phosphatase, vitamin D effects in animal models, 549-550 deficiency prevalence, 659-660 bone, 416 humans, 1408-1409 intake recommendations, 671-672 Alkalosis, hypophosphatemia, 1174 overview of actions, 1406-1408 intervention trials Allergic rhinitis, vitamin D studies, 2013 parathyroid hormone receptor signaling, bone response, 667-669 All-trans retinoic acid (ATRA), leukemia 1414-1415 muscle response, 669 treatment with vitamin D toxicity and ectopic calcification, 590 status influences combination therapy, 1739-1740 toxicity studies, 1409-1411, 1415-1416 age and pubertal maturation, 662 Alopecia vitamin D analog risks, 1418-1419 latitude and season, 661-662 hereditary vitamin-D resistant rickets Arthritis, see Osteoarthritis; Psoriatic obesity, 662 association, 1200, 1223-1224 arthritis; Rheumatoid arthritis race and socioeconomic status, 662 rickets association, 814 Arthroplasty, see Orthopedics sex differences, 662, 669-671 Aluminum toxicity, radiographic findings, 5-ASA, see 5-Aminosalicylic acid status markers 874-875 Association studies bone turnover markers, 666 Alzheimer's disease (AD), vitamin D candidate gene association studies, la:,25-dihydroxyvitamin D, 663-664 studies, 575 1027-1028 fractional calcium absorption, 5-Aminosalicylic acid (5-ASA), genome-wide association studies, 664-665 inflammatory bowel disease 1028-1029 25-hydroxyvitamin D, 659 management, 1885 overview, 1027 intact parathyroid hormone, 664 Analogs, see Vitamin D analogs Asthma AF-2 Anaphylaxis, vitamin D studies, 2012-2013 adolescent vitamin D status, 671 mutation, 239 Angiogenesis clinical features, 2001-2002 vitamin D receptor activation, 105, 108, 110, inhibition by vitamin D in cancer, control, 2008-2010 148,151 1595-1597 intervention trials of vitamin D in acute AFM, see Atomic force microscopy prostate cancer and vitamin D inhibition, respiratory infection, 2005-2006 Aging, see also Elderly; Falls; Fracture 1688-1689 observational studies of vitamin D, klotho studies, 754 vitamin D receptor functions, 543-544 2004 metabolic bone disease, 807 Angiotensin, see Renin-angiotensin system pathogenesis, 2006-2008 vitamin D receptor as longevity nuclear Animal feed prospects for study, 2014 receptor, 160-161 biofortification, 999 vitamin D deficiency during pregnancy and vitamin D synthesis effects, 16 vitamin D intake recommendations, 87-88 late effects on child, 687 2057 2058 INDEX Atherosclerosis glucocorticoid-induced osteoporosis metabolism, 411-413 Bon endothelial dysfunction, 1975-1976 therapy, 1240-1241 sources, 412-413 optimal vitamin D status, 1079-1080 vitamin D metabolism effects, 1262 vitamin D receptor BPH vitamin D BL269, 1475 bacterial artificial chromosome clones Brai intervention studies, 555-556, BL314,1475 studies, 123 ca 1408-1409 BL562,1475 function, 437-438 d~ observational studies, 555 Bladder cancer, vitamin D studies, Wnt in homeostasis, 242-243 overview of actions, 1406-1408 1765-1766 Bone histomorphometry Vitamin D and Omega-3 Trial background, BMD, see Bone mineral density biopsy 2045 BMPs, see Bone morphogenetic proteins adverse effects, 846 Atomic force microscopy (AFM), Body size, vitamin D synthesis effects, indications, 846 inl mineralization analysis, 387 986-987 technique, 845-846 kr Atopic dermatitis, vitamin D studies, Bolus dosing, vitamin D, 1001-1002 bone turnover analysis 2012-2014 Bone, see also Collagen; Fracture; activation frequency, 852 ne ATRA, see All-trans retinoic acid Mineralization; Oral skeleton; formation rates, 852 AUF-I, 430, 500 Osteoblast; Osteoclast; Osteocyte; mineralizing perimeter, 852 vit Autoimmune disease, see specific diseases Rickets; Runx2 remodeling periods, 853 vit Autoimmune polyglandular syndrome bariatric surgery effects, 1016-1018 limitations, 848 type 1, hypocalcemia, 1095 biopsy, see Bone histomorphometry methodology, 846-847 Autophagy calbindin D function, 366-367 mineralization assessment breast cancer, 1658-1659 calcium-sensing receptor function, 437-438 , adjusted apposition rate, 850 BRC innate immunity, 1815 ~-catenin-vitaminD receptor interactions, mineral apposition rate, 849-850 Brea~ 156,243-244 mineralization lag time, 850 BAC, see Bacterial artificial chromosome chromatin remodeling, 311-313 osteoid maturation time, 850 Brem Bacterial artificial chromosome (BAC), CYP27Bl function, 412-413, 587 osteoid measurement, 849 cel vitamin D receptor clones epigenetic mechanism for lineage tetracycline labeling, 848-849 bone cell activity, 123 commitment, 309-310 osteomalacia transgenes in mice, 123-124 fetal development, 626 focal osteomalacia, 852 Bariatric surgery, see Obesity fibroblast growth factor-23 coordination of generalized osteomalacia, 851-852 Basal cell carcinoma, see Skin cancer renal phosphate handling with bone prospects, 857 B cell mineralization and turnover, referents, 847 CYP27Bl/vitamin D receptor knockout 757-758 remodeling studies, 594-596 formation balance assessment vitamin D receptor agonist effects, endochondral bone formation in formation, 853-854 1798-1799 development, 301-303 resorption, 854-855 Benign prostatic hyperplasia (BPH) nuclear organization of regulatory indices, 846 epidemiology, 1931 machinery, 306-308 structural assessment medical treatment, 1933 signaling in formation determinants of bone strength, 855 CY pathogenesis, 1931-1933 bone morphogenetic proteins, 304 three-dimensional approaches, 856 vitamin D receptor agonist studies fibroblast growth factors, 304 two-dimensional approaches, 856 inflammation inhibition, 1935-1936 Wnt, 304-305 terminology, 847-848 lower urinary tract symptoms, gene expression within context of nuclear theory, 846 est! 1931-1933 architecture, 309-311 Bone mineral density (BMD) int~ overview, 1803 gene transactivation by vitamin D receptor, genome-wide association studies, prospects for study, 1937-1938 113, 117-118 1034-1035 pre prostate cell growth control, maternal vitamin D deficiency effects on glucocortiCOid-induced osteoporosis and pro 1933-1934 child later in life, 687 vitamin D response, 1238-1241 vita urethra dysfunction, 1936-1937 mechanical load response, 325-326 idiopathic hypercalciuria and reduction, Beta cell, see Diabetes metastasis and chemokines in osteoclast 1363-1365 vita Bile acids, see also Lithocholic acid regulation, 340-341 measurement, see Dual-energy X-ray Ii derivatives osteoarthritis changes, 1956-1957 absorptiometry; Quantitative metabolism and regulation by nuclear parathyroid hormone function, 730-732 computed tomography v receptors, 1511-1514 parathyroid hormone-related protein optimal vitamin D status, 1073 pathophysiology, 777 function, 734-735 osteoporosis effects of calcium and vitamin structures, 1510 pregnancy and lactation effects, D supplementation, 1133-1134 synthesis and metabolism, 760, 1511-1512 682-684 pubertal bone acquisition, 657-658, types, 775 pubertal bone acquisition, 657-658 660-661 BroWl vitamin A effects on synthesis, 764-765 remodeling, 323-325, 813 Bone morphogenetic proteins (BMPs), bone vitamin D receptor scaffolding of regulatory components for formation signaling, 304 BSP,sl bile acid synthesis regulation, 765-766 combinatorial control of gene Bone scinitigraphy Bumi binding, 766 expression, 313-315 metabolic bone disease diagnosis, 817 BXL-6 detoxification role, 765-766 turnover, 335 overview, 883 BXLOl interaction overview, 1509-1511 turnover markers as vitamin D status Bone sialoprotein (BSP), mineralization role Biliopancreatic diversion, see Obesity markers in adolescence, 666 and vitamin D effects, 392-393, CaffeiJ Bisphosphonates vitamin D 416-417 Calbir INDEX 2059 Bone volume, CYP27B1 knockout studies, apoptosis role, 369-370 hypocalcemia and dietary deficiency, 1099 587 calcium absorption role, 353 influx and adipocyte metabolism, 769
Load more

Recommended publications
  • Controversies in Vitamin D: Summary Statement from an International Conference
    REPORTS AND RECOMMENDATIONS Controversies in Vitamin D: Summary Statement From an International Conference Andrea Giustina,1 Robert A. Adler,2 Neil Binkley,3 Roger Bouillon,4 Peter R. Ebeling,5 Marise Lazaretti-Castro,6 Claudio Marcocci,7 Rene Rizzoli,8 Christopher T. Sempos,9 and John P. Bilezikian10 1Endocrinology and Metabolism, Vita-Salute San Raffaele University, 20122 Milano Italy; 2McGuire Veterans Downloaded from https://academic.oup.com/jcem/article/104/2/234/5148139 by guest on 27 September 2021 Affairs Medical Center and Virginia Commonwealth University School of Medicine, Richmond, Virginia 23249; 3Osteoporosis Clinical Research Program and Institute on Aging, University of Wisconsin-Madison, Madison, Wisconsin 53705; 4Department of Chronic Diseases, Metabolism and Ageing, Laboratory of Clinical and Experimental Endocrinology, Katholieke Universiteit Leuven, Leuven 3000, Belgium; 5Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria 3168, Australia; 6Division of Endocrinology, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, 05437-000 Sao Paulo, Brazil; 7Department of Clinical and Experimental Medicine, University of Pisa, 56124 Pisa, Italy; 8Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, 1211 Geneva 14 Geneva, Switzerland; 9Department of Population Health Sciences, University of Wisconsin-Madison, Madison, Wisconsin 21078; and 10Endocrinology Division, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032 ORCiD numbers: 0000-0002-1570-2617 (J. P. Bilezikian). Context: Vitamin D is classically recognized as a regulator of calcium and phosphorus metabolism. Recent advances in the measurement of vitamin D metabolites, diagnosis of vitamin D deficiency, and clinical observations have led to an appreciation that along with its role in skeletal metabolism, vitamin D may well have an important role in nonclassical settings.
    [Show full text]
  • (SBEM) for the Diagnosis and Treatment of Hypovitaminosis D
    consenso Recomendações da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) para o diagnóstico e tratamento da hipovitaminose D Recommendations of the Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and treatment of hypovitaminosis D Sergio Setsuo Maeda1, Victoria Z. C. Borba2, Marília Brasilio Rodrigues Camargo1, Dalisbor Marcelo Weber Silva3, João Lindolfo Cunha Borges4, Francisco Bandeira5, Marise Lazaretti-Castro1 RESUMO Objetivo: Apresentar uma atualização sobre o diagnóstico e tratamento da hipovitaminose 1 Disciplina de Endocrinologia, D baseada nas mais recentes evidências científicas.Materiais e métodos: O Departamento Universidade Federal de São de Metabolismo Ósseo e Mineral da Sociedade Brasileira de Endocrinologia e Metabologia Paulo, Escola Paulista de Medicina (Unifesp/EPM), São Paulo, SP, Brasil (SBEM) foi convidado a conceber um documento seguindo as normas do Programa Diretrizes 2 Departamento de Clínica Médica, da Associação Médica Brasileira (AMB). A busca dos dados foi realizada por meio do PubMed, Universidade Federal do Paraná Lilacs e SciELO e foi feita uma classificação das evidências em níveis de recomendação, de (UFPR), Curitiba, PR, Brasil 3 Departamento de Clínica acordo com a força científica por tipo de estudo. Conclusão: Foi apresentada uma atualização Médica, Faculdade de Medicina científica a respeito da hipovitaminose D que servirá de base para o diagnóstico e tratamento da Univille, Joinville, SC, Brasil 4 dessa condição no Brasil. Arq Bras Endocrinol Metab. 2014;58(5):411-33 Disciplina de Endocrinologia, Universidade Católica de Brasília Descritores (UCB), Brasília, DF, Brasil 5 Vitamina D; colecalciferol; PTH; osteoporose; deficiência; insuficiência; diagnóstico; tratamento Disciplina de Endocrinologia, Hospital Agamenon Magalhães, Universidade de Pernambuco ABSTRACT (UPE), Escola de Medicina, Recife, PE, Brasil Objective: The objective is to present an update on the diagnosis and treatment of hypovita­ minosis D, based on the most recent scientific evidence.
    [Show full text]
  • Eldecalcitol Is More Effective for Promoting Osteogenesis Than Alfacalcidol in Cyp27b1-Knockout Mice
    bioRxiv preprint doi: https://doi.org/10.1101/349837; this version posted June 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Eldecalcitol is more effective for promoting osteogenesis than alfacalcidol in Cyp27b1-knockout Mice Short title: Osteogenic effect of eldecalcitol Yoshihisa Hirota1,2*¶, Kimie Nakagawa2¶, Keigo Isomoto2¶, Toshiyuki Sakaki3, Noboru Kubodera4, Maya Kamao2, Naomi Osakabe5, Yoshitomo Suhara6, Toshio Okano2* 1 Laboratory of Biochemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan 2 Laboratory of Hygienic Sciences, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan 3 Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, Kurokawa, Imizu, Toyama 939-0398, Japan 4 International Institute of Active Vitamin D Analogs, 35-6, Sankeidai, Mishima, Shizuoka 411-0017, Japan 5 Food and Nutrition Laboratory, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan 6 Laboratory of Organic Synthesis and Medicinal Chemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan ¶ These authors contributed equally to this work. * Corresponding authors: Yoshihisa Hirota Tel.: +81-48-7201-6037; Fax: +81-48-7201-6011; E-mail: hirotay@ shibaura-it.ac.jp Toshio Okano Tel.: (81) 78-441-7524; Fax: (81) 78-441-7524; E-mail: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/349837; this version posted June 18, 2018.
    [Show full text]
  • Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients
    Tohoku J. Exp. Med., 2015, 237, 339-343Effectiveness of Eldecalcitol in Osteoporosis 339 Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients Keijiro Mukaiyama,1 Shigeharu Uchiyama,1 Yukio Nakamura,1 Shota Ikegami,1 Akira Taguchi,2 Mikio Kamimura3 and Hiroyuki Kato1 1Department of Orthopedic Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan 2Department of Oral and Maxillofacial Radiology, Matsumoto Dental University, Shiojiri, Nagano, Japan 3Center for Osteoporosis and Spinal Disorders, Kamimura Orthopaedic Clinic, Matsumoto, Nagano, Japan Alfacalcidol (ALF) and eldecalcitol (ELD) are vitamin D analogues that can be combined with anti-resorption drugs, such as bisphosphonate (BP) for the treatment of osteoporosis (OP). There has been no report comparing the effects of those vitamin D analogs in combination with BPs. Twenty female patients with OP were enrolled, and all of them were treated with ALF and BPs. After switching from ALF to ELD, we examined the effectiveness of ALF and ELD. The averaged age was 69.4 years and the period of BP usage was between 1 to 13.4 years (mean period was 3.7 years). Serum corrected calcium, serum inorganic phosphorus, serum bone specific alkaline phosphatase (BAP), and serum tartrate-resistant acid phosphatase (TRACP)-5b were measured prior to ELD and at 6 months afterwards. Bone mineral density (BMD) of the lumbar spine (L-BMD), femoral neck, and total hip BMD were assessed one year before, prior to, and one year after ELD therapy commencement. Six months after switching from ALF to ELD, BAP and TRACP-5b values significantly decreased. After one year of ALF therapy, L-BMD, total hip BMD and femoral neck H-BMD values slightly increased.
    [Show full text]
  • Eldecalcitol, a Vitamin D Analog, Reduces Bone Turnover and Increases Trabecular and Cortical Bone Mass, Density, and Strength in Ovariectomized Cynomolgus Monkeys
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Bone 57 (2013) 116–122 Contents lists available at ScienceDirect Bone journal homepage: www.elsevier.com/locate/bone Original Full Length Article Eldecalcitol, a vitamin D analog, reduces bone turnover and increases trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys Susan Y. Smith a, Nancy Doyle a, Marilyne Boyer a, Luc Chouinard a, Hitoshi Saito b,⁎ a Bone Research, Charles River Laboratories Preclinical Services Montreal, Senneville, Quebec H9X 3R3, Canada b Medical Science Department, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan article info abstract Article history: Vitamin D insufficiency is common in elderly people worldwide, and intake of supplementary calcium and Received 28 February 2013 vitamin D is recommended to those with a high risk of fracture. Several clinical studies and meta-analyses Revised 24 May 2013 have shown that calcium and vitamin D supplementation reduces osteoporotic fractures, and a strong correlation Accepted 7 June 2013 exists between vitamin D status and fracture risk. Vitamin D supplementations improve calcium balance in the Available online 14 June 2013 body; however, it remains unclear whether vitamin D directly affects bone metabolism. Recently, eldecalcitol Edited by: Toshio Matsumoto (ELD), an active form of vitamin D analog, has been approved for the treatment of osteoporosis in Japan. A 3-year clinical trial showed ELD treatment increased lumbar spine bone mineral density (BMD) and reduced frac- Keywords: ture risk in patients with osteoporosis. To evaluate the mechanism of ELD action in bone remodeling, ovariecto- Osteoporosis mized cynomolgus monkeys were treated with 0.1 or 0.3 μg/day of ELD for 6 months.
    [Show full text]
  • Does the High Prevalence of Vitamin D Deficiency in African Americans
    nutrients Review Does the High Prevalence of Vitamin D Deficiency in African Americans Contribute to Health Disparities? Bruce N. Ames 1, William B. Grant 2,* and Walter C. Willett 3,4 1 Molecular and Cell Biology, Emeritus, University of California, Berkeley, CA 94720, USA; [email protected] 2 Sunlight, Nutrition and Health Research Center, San Francisco, CA 94164-1603, USA 3 Departments of Nutrition and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; [email protected] 4 Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA * Correspondence: wbgrant@infionline.net Abstract: African Americans have higher incidence of, and mortality from, many health-related problems than European Americans. They also have a 15 to 20-fold higher prevalence of severe vitamin D deficiency. Here we summarize evidence that: (i) this health disparity is partly due to insufficient vitamin D production, caused by melanin in the skin blocking the UVB solar radiation necessary for its synthesis; (ii) the vitamin D insufficiency is exacerbated at high latitudes because of the combination of dark skin color with lower UVB radiation levels; and (iii) the health of individuals with dark skin can be markedly improved by correcting deficiency and achieving an optimal vitamin D status, as could be obtained by supplementation and/or fortification. Moderate-to-strong evidence exists that high 25-hydroxyvitamin D levels and/or vitamin D supplementation reduces risk for many adverse health outcomes including all-cause mortality rate, adverse pregnancy and birth Citation: Ames, B.N.; Grant, W.B.; outcomes, cancer, diabetes mellitus, Alzheimer’s disease and dementia, multiple sclerosis, acute Willett, W.C.
    [Show full text]
  • Comparison of the Effects of Native Vitamin D and Eldecalcitol on Muscular Strength and Dynamic Balance in Patients with Postmenopausal Osteoporosis
    doi: 10.2490/prm.20200026 Progress in Rehabilitation Medicine 2020; Vol. 5, 20200026 ORIGINAL ARTICLE Comparison of the Effects of Native Vitamin D and Eldecalcitol on Muscular Strength and Dynamic Balance in Patients with Postmenopausal Osteoporosis Naohisa Miyakoshi, MD, PhD Norimitsu Masutani, MD, PhD Yuji Kasukawa, MD, PhD Daisuke Kudo, MD, PhD Kimio Saito, MD, PhD Toshiki Matsunaga, MD, PhD and Yoichi Shimada, MD, PhD Objectives: Previous studies have suggested that the effects of vitamin D in preventing osteopo- rotic fractures result in part from its influence on fall prevention. However, the effects of vitamin D on dynamic balance as a contributor to fall prevention have not been fully evaluated. Moreover, few studies have compared the effects of native and active forms of vitamin D. The objective of this preliminary randomized prospective study was to compare the effects of native vitamin D and eldecalcitol on muscular strength and dynamic balance in postmenopausal patients undergo- ing denosumab treatment for osteoporosis. Methods: A total of 30 women with postmenopausal osteoporosis were randomly assigned to a native D group (administered denosumab and native vitamin D with calcium) or an ELD group (administered denosumab and eldecalcitol) and were followed up for 6 months. The following parameters were compared: the strengths of the back extensor and lower extremity muscles; static balance evaluated using the one-leg standing test; and dynamic balance evaluated using the 10-m walk test, the functional reach test, the timed up and go test, and the total length of the trajectory of the center of gravity (LNG) measured using a dynamic sitting balance measurement device.
    [Show full text]
  • Eldecalcitol Is More Effective for Promoting Osteogenesis Than Alfacalcidol in Cyp27b1-Knockout Mice
    bioRxiv preprint doi: https://doi.org/10.1101/349837; this version posted June 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Eldecalcitol is more effective for promoting osteogenesis than alfacalcidol in Cyp27b1-knockout Mice Short title: Osteogenic effect of eldecalcitol Yoshihisa Hirota1,2*¶, Kimie Nakagawa2¶, Keigo Isomoto2¶, Toshiyuki Sakaki3, Noboru Kubodera4, Maya Kamao2, Naomi Osakabe5, Yoshitomo Suhara6, Toshio Okano2* 1 Laboratory of Biochemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan 2 Laboratory of Hygienic Sciences, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan 3 Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, Kurokawa, Imizu, Toyama 939-0398, Japan 4 International Institute of Active Vitamin D Analogs, 35-6, Sankeidai, Mishima, Shizuoka 411-0017, Japan 5 Food and Nutrition Laboratory, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan 6 Laboratory of Organic Synthesis and Medicinal Chemistry, Department of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, 307 Fukasaku, Minuma-ku, Saitama 337-8570, Japan ¶ These authors contributed equally to this work. * Corresponding authors: Yoshihisa Hirota Tel.: +81-48-7201-6037; Fax: +81-48-7201-6011; E-mail: hirotay@ shibaura-it.ac.jp Toshio Okano Tel.: (81) 78-441-7524; Fax: (81) 78-441-7524; E-mail: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/349837; this version posted June 18, 2018.
    [Show full text]
  • Eldecalcitol Replaces Endogenous Calcitriol but Does Not Fully
    Journal of Steroid Biochemistry & Molecular Biology 144 (2014) 189–196 CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Contents lists available at ScienceDirect Journal of Steroid Biochemistry and Molecular Biology j ournal homepage: www.elsevier.com/locate/jsbmb Original Article Eldecalcitol replaces endogenous calcitriol but does not fully ଝ compensate for its action in vivo ∗,1 1 Hitoshi Saito , Suguru Harada Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan a r t i c l e i n f o a b s t r a c t Article history: Calcitriol (1␣,25-dihydroxyvitamin D3, 1␣,25(OH)2D3) is an essential hormone that works in cooper- Received 1 August 2013 ation with parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF-23) to regulate calcium Received in revised form and phosphorus homeostasis. Previous in vivo studies in rats have shown that eldecalcitol, a vitamin D 17 November 2013 analog, is more active than calcitriol in stimulating calcium and phosphorus absorption in the intestine Accepted 19 November 2013 and in increasing serum FGF-23, but is not as active in suppressing blood PTH. However, those results Available online 26 November 2013 are problematic because administration of exogenous eldecalcitol or calcitriol affects the synthesis and degradation of endogenous calcitriol, and competes for binding to vitamin D receptor (VDR) in target tis- Keywords: Eldecalcitol sues. Therefore, we tried to evaluate the ‘true biological activity in vivo’ of each compound by comparing VDR their biological activities with respect to their blood concentrations. Calcium In VDR gene knockout mice, calcitriol and eldecalcitol did not affect either serum or urinary calcium Phosphorus levels, and also did not induce the expression of target genes.
    [Show full text]
  • Supplementary Table 1: List of Oral Vitamin D
    Supplementary material BMJ Open Supplementary Table 1: List of oral vitamin D analogues Name Indication Brand name Paricalcitol (19-nor- Secondary Zemplar® (Abbott) 1α,25(OH)2D2) hyperparathyroidism Doxercalciferol Secondary Hectorol® (Genzyme corp) (1α(OH)D2) hyperparathyroidism Falecalcitriol (26,27 F6- Secondary Fulstan® (Dainippon 1α,25(OH)2D3) hyperparathyroidism Sumitomo) and Hornel® (Japan only) (Taisho Yakuhin) Maxacalcitol (22oxa- Secondary Oxarol® (Chugai 1α,25(OH)2D3) hyperparathyroidism and Pharmaceutical) psoriasis (Japan only) Eldecalcitol (2β-(3- Osteoporosis (Japan only) Edirol® (Chugai hydroxypropoxy)- Pharmaceutical) 1α,25(OH)2D3) Lin L-Y, et al. BMJ Open 2019; 9:e031867. doi: 10.1136/bmjopen-2019-031867 Supplementary material BMJ Open Supplementary Table 2: Search strategies in Medline (Ovid) Item Search Terms Herpesviruses 1 (HHV adj1 ("1" or "2" or "3" or "4" or "5" or "6" or "7" or "8")) or (HHV?1 or HHV?2 or HHV?3 or HHV?4 or HHV?5 or HHV?6 or HHV?7 or HHV?8) 2 exp Herpesviridae Infections/ or exp Herpesviridae/ 3 herpes* or herpesvir* 4 exp Herpes Simplex/ 5 herpes simplex 6 HSV-1 or HSV?1 7 Cold sore* 8 exp Herpes Labialis/ 9 Herpes Labialis 10 Herpes* adj2 Labial* 11 Hsv-2 or HSV?2 or (genit* herpes* or genit* sores) 12 exp Herpes Zoster/ 13 herpes zoster 14 vz virus* or VZV 15 varicella? 16 chickenpox or Chicken?pox 17 shingle* 18 neuralgia adj1 post?herpetic) 19 Epstein-Barr virus* or (burkitt lymphoma adj2 virus*) or e?b virus* or ((eb or e-b) adj virus*) or ebv or Epstein?barr virus* or infectious mononucleosis
    [Show full text]
  • Inhibition of Vitamin D Analog Eldecalcitol on Hepatoma in Vitro and in Vivo
    Open Medicine 2020; 15: 663–671 Research Article Limin Ye*, Liyi Zhu, Jinglin Wang, Fei Li Inhibition of vitamin D analog eldecalcitol on hepatoma in vitro and in vivo https://doi.org/10.1515/med-2020-0137 in spite of advanced medical diagnosis by liver trans- received April 2, 2020; accepted June 9, 2020 plantation or ablation treatment, new molecular tech- [ ] Abstract: Hepatoma is a serious liver cancer with high nologies 1,2 . The key technical challenge is how to - morbidity and mortality. Eldecalcitol (ED-71),avitaminD identify the higher risk stage of malignant transforma [ ] analog, is extensively used as anti-cancer agent in vitro. tion patients 3 . Although histopathology diagnostics ff Hepatocellular carcinoma cell, SMMC-7721 cell lines were combined with advances in di erent forms of surgical or used in this study. Transwell assay, cell apoptosis and cell chemotherapy therapy have improved the results for [ ] cycle detection assays were investigated after treatment with tumor patients to a large extent 4,5 , there are still no ff ED-71 and phosphate buffered saline (PBS) as control. Sizes of e ective drugs used to inhibit tumor cell growth [ ] tumors were measured after ED-71 treatment in a mouse clinically 6 . The only systemic therapy drug for HCC model. E-cadherin and Akt gene expressions were detected by is sorafenib, which is an oral multikinase inhibitor only [ ] real-time PCR (RT-PCR). The results showed that cell invasion for patients with inoperable or advanced HCC 7 . fi and migration were decreased markedly after ED-71 treatment Therefore, there should be many challenges for nding compared to control group.
    [Show full text]
  • Treatment of Osteoporosis with Eldecalcitol, a New Vitamin D Analog Open Access to Scientific and Medical Research DOI
    Journal name: Drug Design, Development and Therapy Article Designation: Review Year: 2016 Volume: 10 Drug Design, Development and Therapy Dovepress Running head verso: Xu et al Running head recto: Treatment of osteoporosis with eldecalcitol, a new vitamin D analog open access to scientific and medical research DOI: http://dx.doi.org/10.2147/DDDT.S84264 Open Access Full Text Article REVIEW Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials Zhixing Xu1 Objective: Eldecalcitol (ELD) is an active form of vitamin D analog that has been approved Changchun Fan2 for the treatment of osteoporosis in Japan. Over recent years, a number of multicenter, random- Xuechun Zhao3 ized controlled clinical trials have been conducted. Our goal is to comprehensively summarize Hairong Tao1 the results from these studies. Methods: We searched the databases MEDLINE, EMBASE, and Cochrane Central Register 1Department of Orthopedic Surgery, The Third People’s Hospital Affiliated of Controlled Trials up to February 28, 2015. Each database was searched using search terms to Shanghai Jiaotong University “Eldecalcitol” and “ED-71” and the results were combined. The retrieved data from three inde- School of Medicine, Shanghai, People’s pendent clinical trials included a total of 1,332 patients with osteoporosis. After the data were Republic of China; 2Department of Orthopedic Surgery, Jinan Military pooled from three trials, RevMan software was used to conduct meta-analyses to determine the General Hospital, 3Department of effects of ELD on bone mineral density (BMD) and bone turnover marker (BTM) type I collagen Orthopedic Surgery, The Third amino-terminal telopeptide (NTX).
    [Show full text]